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Third consensus on medical
treatment of metastatic breast
cancer
With great interest, I read the article by Beslija et al. [1]
published recently in this journal. The range of topics touched
is very broad and I believe that this article gives an excellent
overview on the management of advanced breast cancer.
However, I wish to point out a subject that was not treated
by this article, which I believe is important: because breast
cancer is a chemosensitive disease, many chemotherapeutic
agents are now available. As mentioned by the authors,
multidrug chemotherapy is not necessarily better than single-
drug treatments, archiving marginally better response rates at
higher cost of toxicity. Particularly for slowly progressive
disease, single-drug therapy seems to be a valuable option. The
logical consequence becomes that many women are treated
with several lines of single-agent chemotherapy.
The chemotherapeutic agents mentioned in this article are
anthracyclines, taxanes, capecitabine, vinorelbine, gemcitabine,
epothilones, platinum, metronomic therapy as well as the
various biological agents. Therefore, the number of potential
lines is vast. Most of these agents have demonstrated their
clinical activity in first- or second-line setting. Little evidence is
available about the efficacy and the contribution to quality of
life of these agents in third-, fourth-, fifth- or x-line therapy.
Dufresne et al. [2] found in a retrospective study of 900
patients a median time of disease control was 9.3, 5.9, 4.63, 4.1
and 0.23 months in first, second, third, fourth and fifth lines,
respectively. I wonder if these women were just unlucky to
survive long enough (usually between 2 and 3 years) to be
treated with most of these agents without any evidence of real
clinical benefit beyond second- or third-line therapy? Decreased
quality of life and increased health care costs might be the
consequences.
I indicate, therefore, that breast cancer researcher should
turn their attention to this important topic. I propose that the
international panel for the treatment of metastatic breast cancer
should address this issue in their next publication.
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